{"name":"Kowa Research Institute, Inc.","slug":"kowa-research-institute-inc","ticker":"","exchange":"","domain":"kowaresearchinstitute.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-01","label":"Livalo Phase 3 readout (HIV Infections, Weight Gain)","drug":"Livalo","drugSlug":"livalo","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"K-161","genericName":"K-161","slug":"k-161","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Livalo","genericName":"Livalo","slug":"livalo","indication":"Familial hypercholesterolemia","status":"discontinued"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"C: Pitavastatin IR 8 mg","genericName":"C: Pitavastatin IR 8 mg","slug":"c-pitavastatin-ir-8-mg","indication":"Other","status":"phase_1"},{"name":"Placebo (for K-877)","genericName":"Placebo (for K-877)","slug":"placebo-for-k-877","indication":"Control in clinical trials for K-877","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Darunavir/Ritonavir (Prezista)","genericName":"Darunavir/Ritonavir (Prezista)","slug":"darunavir-ritonavir-prezista","indication":"HIV-1 infection in treatment-experienced patients","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Pitavastatin (NK-104)","genericName":"Pitavastatin (NK-104)","slug":"pitavastatin-nk-104","indication":"Hypercholesterolemia and dyslipidemia","status":"marketed"}]}],"pipeline":[{"name":"K-161","genericName":"K-161","slug":"k-161","phase":"phase_3","mechanism":"K-161 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"C: Pitavastatin IR 8 mg","genericName":"C: Pitavastatin IR 8 mg","slug":"c-pitavastatin-ir-8-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Darunavir/Ritonavir (Prezista)","genericName":"Darunavir/Ritonavir (Prezista)","slug":"darunavir-ritonavir-prezista","phase":"marketed","mechanism":"Darunavir is an HIV protease inhibitor that blocks the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.","indications":["HIV-1 infection in treatment-experienced patients","HIV-1 infection in treatment-naïve patients"],"catalyst":""},{"name":"Livalo","genericName":"Livalo","slug":"livalo","phase":"discontinued","mechanism":"Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Retinoic acid receptor RXR-alpha","indications":["Familial hypercholesterolemia","Hypercholesterolemia","Mixed hyperlipidemia"],"catalyst":""},{"name":"Pitavastatin (NK-104)","genericName":"Pitavastatin (NK-104)","slug":"pitavastatin-nk-104","phase":"marketed","mechanism":"Pitavastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","indications":["Hypercholesterolemia and dyslipidemia","Primary prevention of cardiovascular disease","Secondary prevention of cardiovascular events in patients with established coronary artery disease"],"catalyst":""},{"name":"Placebo (for K-877)","genericName":"Placebo (for K-877)","slug":"placebo-for-k-877","phase":"phase_3","mechanism":"This is a placebo, meaning it has no active therapeutic effect.","indications":["Control in clinical trials for K-877"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":2,"phase_1":1,"marketed":2,"discontinued":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}